Bakers and Clutz advise on pharmaceutical offload (1)

Firms: Baker & McKenzie (Valeant Pharmaceuticals); Clayton Utz (Ironbridge and Archer Capital) Deal: NYSE-listed, Canada-based Valeant Pharmaceuticals acquisition of Australian-based iNova…

Lawyers Weekly • 11 January 2012 • Big Law

Firms: Baker & McKenzie (Valeant Pharmaceuticals); Clayton Utz (Ironbridge and Archer Capital)

You’re out of free articles for this month

Username or Email

Password Forgot password?

Keep me signed in on this device.

First Name

Last Name

Mobile

Organisation Type

By becoming a member, I agree to receive information and promotional messages from Lawyers Weekly. I can opt out of these communications at any time. For more information, please visit our Privacy Statement.

Need help signing up? Visit the Help Centre.

Deal: NYSE-listed, Canada-based Valeant Pharmaceuticals acquisition of Australian-based iNova Pharmaceuticals from Ironbridge and Archer Capital. Deal officially closed on 21 December

Area: M&A

VIEW ALL

Value: $625 million upfront and up to an additional $75 million in potential milestones

Key players: The Bakers team was led by Sydney-based partner David Egan and associate Michael Dearden

You need to be a member to post comments. Become a member for free today!

Lawyers Weekly - legal news for Australian lawyers

SECTIONS

MORE

Bakers and Clutz advise on pharmaceutical offload (1)

OUR PLATFORMS AND BRANDS

EVENTS AND SUMMITS

PODCASTS

LEARNING AND EDUCATION

MOMENTUM MARKETS NETWORK

LINKS

STAY CONNECTED